- Home
- GAME vs RNXT Comparison
GAME vs RNXT Comparison
Compare GAME & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAME | RNXT |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 36.4M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GAME | RNXT |
|---|---|---|
| Price | $0.44 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | ★ 1.3M | 334.7K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,810,388.00 | $928,000.00 |
| Revenue This Year | N/A | $2,795.35 |
| Revenue Next Year | $16.44 | $272.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 188.95 | N/A |
| 52 Week Low | $0.37 | $0.70 |
| 52 Week High | $2.87 | $1.69 |
Technical Indicators
Market Signals| Indicator | GAME | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 44.89 | 53.98 |
| Support Level | $0.43 | $0.98 |
| Resistance Level | $0.48 | $1.08 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 57.76 | 50.00 |
Price Performance
Historical ComparisonAbout GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.